Drugs / Blackcurrant (BC) extract
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07365514 Comparator | Feb 2026 → Feb 2028 expected | postmenopausal osteoporosis | University of Connecticut | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04431960 Comparator | Jul 2021 → Oct 2022 | cardiovascular disorder, postmenopausal osteoporosis | University of Connecticut | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Blackcurrant (BC) extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07365514 ↗ |
| Action | Inhibit | “Daily BC consumption for 6 months mitigated bone loss in this population potentially through modulating the gut microbiota composition and suppressing osteoclastogenic cytokines.” PMID 39019119 ↗ Jul 2024 |